Articles: function.
-
ILD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: This prospective study assessed the effect of inhaled N-acetylcysteine (NAC) monotherapy on lung function and redox balance in patients with idiopathic pulmonary fibrosis (IPF). ⋯ The following authors have nothing to disclose: Sakae Homma, Yoko Muramatsu, Keishi Sugino, Susumu Sakamoto, Junko Tatebe, Toshisuke MoritaNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Cardiogenic pulmonary edema occurring unilaterally is rare and presents diagnostic difficulties. ⋯ UCPE is an uncommon presentation; it should be considered in patients with unilateral pulmonary infiltrates and severely impaired left ventricular function or mitral valve diseases to avoid delay in diagnosis and appropriate treatment.Reference #1: Attias D, Mansencal N. Prevalence, characteristics, and outcomes of patients presenting with cardiogenic unilateral pulmonary edema. Circulation. 2010;122:1109-1115.Reference #2: Nitzan O, Saliba WR, Goldstein LH. Unilateral pulmonary edema: a rare presentation of congestive heart failure. Am J Med Sci. 2004; 327: 362-364Reference #3: Choi HS, Choi H, Han S, et al. Pulmonary edema during pregnancy: unilateral presentation is not rare. Circ J 2002;66:623-6DISCLOSURE: The following authors have nothing to disclose: Jessica Quah, Tan Keng LeongNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). The BEACON study evaluated the efficacy and safety of QVA149 compared with the concurrent administration of indacaterol and glycopyrronium (IND+GLY). ⋯ The study demonstrated that QVA149 provides benefits of dual bronchodilation in a single inhaler device, making it a more convenient treatment option for patients with moderate-to-severe COPDDISCLOSURE: Ronald Dahl: Consultant fee, speaker bureau, advisory committee, etc.: In the past 3 years, Professor Dahl has received compensation for consulting with Boehringer-Ingelheim, Novartis, Vectura, Roche, Elevation Pharma and Norpharma; has undertaken research funded by AstraZeneca, Boehringer- Ingelheim, C hiesi, GlaxoSmithKline, Novartis, ALK-Abello and Stallergenes; has participated in educational activities sponsored by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, ALK-Abello, Novartis, Almirall. Dalal Jadayel: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
The use of mechanical circulatory support (MCS) devices has increased sixfold since 2006. Although there is an established legal and ethical consensus that patients have the right to withdraw and withhold life-sustaining interventions when burdens exceed benefits, this consensus arose prior to the widespread use of MCS technology and is not uniformly accepted in these cases. ⋯ Our center recently encountered the challenge of an awake and functionally improving patient with a total artificial heart (TAH) who requested its deactivation. We present a narrative description of this case with discussion of the following questions: (1) Is it ethically permissible to deactivate this particular device, the TAH? (2) Are there any particular factors in this case that are ethical contraindications to proceeding with deactivation? (3) What are the specific processes necessary to ensure a compassionate and respectful deactivation? (4) What proactive practices could have been implemented to lessen the intensity of this case's challenges? We close with a list of recommendations for managing similar cases.
-
TransplantationSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: In order to identify the characteristics of late-onset non-infectious pulmonary complications (LONIPCs) in children who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), we retrospectively evaluated the incidence, characteristics, and outcomes of LONIPCs in these patients. ⋯ The following authors have nothing to disclose: Jong-seo Yoon, Hwan Soo Kim, Jae Wook Lee, Yoon Hong Chun, Nack Gyun Chung, Hyun Hee Kim, Bin Cho, Hack Ki Kim, Joon Sung LeeNo Product/Research Disclosure Information.